---
title: "State-Level Estimates of Hepatitis C Virus Prevalence in the US, 2017–2020"
id: "medrxiv-1-estimating-hepatitis-c-virus-prevalence-in-us-states-and-the-district-of"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-estimating-hepatitis-c-virus-prevalence-in-us-states-and-the-district-of"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1?rss=1"
published_at: "2026-10-05T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# State-Level Estimates of Hepatitis C Virus Prevalence in the US, 2017–2020
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-estimating-hepatitis-c-virus-prevalence-in-us-states-and-the-district-of
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1?rss=1)
- **Published At:** 2026-10-05T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study produced **state-level estimates** of adult **Hepatitis C virus (HCV)** prevalence for 48 US states and the District of Columbia covering 2017–2020 using a statistical modeling approach. - Researchers adapted a **Bayesian spatial integrated abundance model** that combined six HCV-related data sources to infer population prevalence, since direct observation is not possible. - The six integrated outcomes were: reported acute and chronic surveillance cases, HCV-related deaths, HCV observations in MarketScan administrative claims, HCV diagnoses among Medicaid recipients, and Medicaid direct-acting antiviral (DAA) treatment records. - Estimates were anchored to an existing national prevalence estimate and the model adjusted for data-source selection effects, state-level heterogeneity in HCV risk factors, and geospatial correlation. - The overall estimated average prevalence across the 48 states and DC was **1.32%** (95% credible interval [CrI] 0.94%–1.80%), corresponding to an estimated **3.33 million** adults with HCV (95% CrI: 2.37–4.65 million). - State prevalence ranged from **0.74%** (North Dakota) to **2.22%** (Oklahoma), with a median state-specific prevalence of 1.27%. - Higher prevalence clustered in South Central states, Appalachia, and the West; lower prevalence occurred in the upper Midwest, Southeast, and New England. Ten states accounted for **56%** of estimated infections. - Sensitivity analyses showed stability of estimates, with most differences under one percentage point. - The estimates serve as a pre-2021 baseline before federal expansion of HCV surveillance funding and highlight differing jurisdictional resource needs for elimination efforts. - Data use agreements restrict sharing of MarketScan and Medicaid inputs; other data sources are publicly available. The Emory IRB determined the study did not constitute human subjects research because it used de-identified secondary data. - The authors declared no competing interests and reported compliance with reporting and ethical guidelines.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=VLZpwjjyj0ewoVJeU.qibjlxlP9Gt14awoPJc19Rupo-1791243656.4049003-1.2.1.1-X7VGjH0FQ2nGkdNpn7Vy7Ik__yUU6zEKkq.SZY_8FneWwTAhiiJK2mzL9DoL19E9) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Estimating Hepatitis C Virus Prevalence in US States and the District of Columbia, 2017-2020 Heather Bradley, [ View ORCID Profile](http://orcid.org/0000-0002-4219-1840)Ya-Hui Yu, Lanxin Li, Shashi N Kapadia, [ View ORCID Profile](http://orcid.org/0000-0002-7728-0587)Patrick S Sullivan, [ View ORCID Profile](http://orcid.org/0000-0003-0244-7458)Eric William Hall doi: https://doi.org/10.64898/2026.09.29.26364309 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Heather Bradley 1 Emory University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Heather%2BBradley%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bradley%20H&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AHeather%2BBradley%2B) Ya-Hui Yu 1 Emory University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ya-Hui%2BYu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Yu%20Y&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AYa-Hui%2BYu%2B) * [ORCID record for Ya-Hui Yu](http://orcid.org/0000-0002-4219-1840 "Open in new tab") * For correspondence: ya-hui.yu@emory.edu Lanxin Li 2 University of Edinburgh; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Lanxin%2BLi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Li%20L&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALanxin%2BLi%2B) Shashi N Kapadia 3 Weill Cornell Medicine; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Shashi%2BN%2BKapadia%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kapadia%20SN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AShashi%2BN%2BKapadia%2B) Patrick S Sullivan 1 Emory University; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Patrick%2BS%2BSullivan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sullivan%20PS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3APatrick%2BS%2BSullivan%2B) * [ORCID record for Patrick S Sullivan](http://orcid.org/0000-0002-7728-0587 "Open in new tab") Eric William Hall 4 Oregon Health & Science University * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Eric%2BWilliam%2BHall%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hall%20EW&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEric%2BWilliam%2BHall%2B) * [ORCID record for Eric William Hall](http://orcid.org/0000-0003-0244-7458 "Open in new tab") * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1314071/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1314071/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1314071/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1314071/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1314071/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1314071/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Background State-level estimates of hepatitis C virus (HCV) prevalence are needed to guide resource allocation and to provide a baseline against which to measure progress toward elimination goals. Population prevalence is not directly observable, requiring estimation from indirect data sources. Methods We adapted a Bayesian spatial integrated abundance model to estimate state-level HCV prevalence during 2017-2020 across 48 states and the District of Columbia. The model integrated six HCV-related outcomes: acute and chronic surveillance cases, HCV-related deaths, observations of HCV in [MarketScan] administrative claims data, diagnoses of HCV in Medicaid recipients, and treatment with direct-acting antivirals in Medicaid recipients. Estimates were anchored to a national prevalence estimate, and the model accounted for data source-specific selection, heterogeneity in HCV risk factors across states, and geospatial correlation. Results Estimated average prevalence was 1.32% (95% credible interval [CrI]: 0.94%-1.80%), corresponding to 3.33 million (95% CrI: 2.37-4.65 million) adults with HCV infection across 48 states and DC. State estimates ranged from 0.74% in North Dakota to 2.22% in Oklahoma (median state-specific prevalence, 1.27%), with higher prevalence concentrated in South Central states, Appalachia, and the West, and the lower prevalence in the upper Midwest, Southeast, and New England. Ten states accounted for 56% of estimated infections. Estimates were stable in sensitivity analyses (most differences The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.29.26364338v1 "Model-guided placement of decentralized diagnostics for spatial control of the 2026 Bundibugyo Ebola epidemic")[Next ](https://www.medrxiv.org/content/10.64898/2026.10.03.26364663v1 "A Semi-Automated Interactive Annotation Framework for Intraoperative Neurosurgical Ultrasound: A Proof-of-Concept Study") Posted October 05, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/10/05/2026.09.29.26364309.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.29.26364309v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/10/05/2026.09.29.26364309.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Estimating Hepatitis C Virus Prevalence in US States and the District of Columbia, 2017-2020 Heather Bradley, Ya-Hui Yu, Lanxin Li, Shashi N Kapadia, Patrick S Sullivan, Eric William Hall medRxiv 2026.09.29.26364309; doi: https://doi.org/10.64898/2026.09.29.26364309 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.29.26364309v1%26text%3DEstimating%2520Hepatitis%2520C%2520Virus%2520Prevalence%2520in%2520US%2520States%2520and%2520the%2520District%2520of%2520Columbia%252C%25202017-2020 "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.29.26364309v1%26t%3DEstimating%2520Hepatitis%2520C%2520Virus%2520Prevalence%2520in%2520US%2520States%2520and%2520the%2520District%2520of%2520Columbia%252C%25202017-2020 "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.29.26364309v1%26title%3DEstimating%2520Hepatitis%2520C%2520Virus%2520Prevalence%2520in%2520US%2520States%2520and%2520the%2520District%2520of%2520Columbia%252C%25202017-2020%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.29.26364309v1%26title%3DEstimating%2520Hepatitis%2520C%2520Virus%2520Prevalence%2520in%2520US%2520States%2520and%2520the%2520District%2520of%2520Columbia%252C%25202017-2020 "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.29.26364309) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.29.26364309v1&count=horizontal&via=&text=Estimating%20Hepatitis%20C%20Virus%20Prevalence%20in%20US%20States%20and%20the%20District%20of%20Columbia%2C%202017-2020&counturl=www.medrxiv.org/content/10.64898/2026.09.29.26364309v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (626) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (914) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (340) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4885) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (486) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (421) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (659) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1643) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16063) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (34) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1218) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7128) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (736) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1072) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5122) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1447) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1792) * [Hematology](https://www.medrxiv.org/collection/hematology) (590) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1355) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16357) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1184) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (678) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (156) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (729) * [Neurology](https://www.medrxiv.org/collection/neurology) (7385) * [Nursing](https://www.medrxiv.org/collection/nursing) (370) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1102) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1263) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1010) * [Oncology](https://www.medrxiv.org/collection/oncology) (3656) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1066) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (399) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (459) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (483) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (142) * [Pathology](https://www.medrxiv.org/collection/pathology) (711) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1822) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (741) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (776) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5986) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9833) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2464) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1479) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1256) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (651) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (786) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (588) * [Surgery](https://www.medrxiv.org/collection/surgery) (786) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (107) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (310) * [Urology](https://www.medrxiv.org/collection/urology) (298) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/c
## Related Clinical Research

- [GSK wins approval for hepatitis B therapy as biotech news ripples through sector](https://medichelpline.com/clinical-feed/stat-news-0-stat-gsk-picks-up-hep-b-drug-approval.md)
- [Immune checkpoint inhibitor–related multi-organ injury with severe pneumonia: case report (Frontie](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-immune-checkpoint-inhibitor-induced-multi-organ-immune-damage-complicated-by.md)
- [Monocyte phenotypes associated with peri‑coronary inflammation in people with and without HIV](https://medichelpline.com/clinical-feed/frontiers-in-immunology-15-distinct-monocyte-phenotypes-are-associated-with-peri-coronary-inflammation-in.md)
- [Reflecting on 50 Years of Interleukin-2: Advancements in Immunotherapy and Retrovirology](https://medichelpline.com/clinical-feed/stat-news-2-opinion-50-years-ago-my-colleagues-and-i-pursued-basic-research-science-that.md)
- [Model-guided placement of decentralized diagnostics to limit spatial spread of the 2026 Bundibugyo](https://medichelpline.com/clinical-feed/medrxiv-2-model-guided-placement-of-decentralized-diagnostics-for-spatial-control-of-the.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.